Иркутская государственная медицинская академия последипломного образованияфилиал федерального государственного бюджетного образовательного учреждения дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации Россия, 664049 г. Иркутск, м-н Юбилейный 100 Цель. В виду социальной значимости противоопухолевых лекарственных препаратов (ЛП) цель исследования -провести сравнительный анализ ассортимента отечественных и зарубежных противоопухолевых ЛП, входящих в перечни жизненно необходимых и важнейших лекарственных препаратов (ЖНВЛП) в 2013 и 2018 гг. в аспекте импортозамещения. Материалы и методы. Исследование проведено сравнением данных о зарегистрированных противоопухолевых препаратах, входящих в перечни ЖНВЛП в 2013 и 2018 гг. в Государственном реестре лекарственных средств. Статистическая обработка полученных данных была проведена методом z-критерия Фишера. Результаты. Всего в РФ на 2013 год было зарегистрировано 286 торговых наименований противоопухолевых ЛП, из них российского производства 94 препарата, т.е. 33%. Фармацевтических субстанций отечественного производства в анализируемой группе в 2013 году было 19, что составляло 27% от 71 МНН (Международное непатентованное наименование). В 2018 году по 71 МНН зарегистрировано 393 торговых наименования противоопухолевых ЛП, из них российского производства -162 препарата, т.е. 41%. Выявлена статистически значимая положительная тенденция увеличения количества противоопухолевых препаратов отечественного производства с 2013 года по 2018 -на 8%. Заключение. В целях увеличения объема импортозамещения при производстве противоопухолевых ЛП необходимо обеспечить государственную поддержку российских производителей, впервые регистрирующих отечественные аналоги. Особое внимание следует уделить производству отечественных фармацевтических субстанций, без которых невозможно обеспечить лекарственную безопасность страны. Ключевые слова: лекарственные средства, лекарственные препараты, импортозамещение, фармацевтические субстанции, противоопухолевые лекарственные препараты
Introduction. Due to the high demand for custom-made medicines, the aim of this study was to analyze the physical availability of custom-made medicines for the population of the Irkutsk region. Materials and methods. A comparative analysis of the number of production pharmacies in the Irkutsk region in 2000 and 2019 was carried out. The analysis of the problems of opening production pharmacies is carried out. Results. The analysis found that in 2000 in the Irkutsk region there were 166 production pharmacies, and in 2019 only 19 remained, i.e. there was a decrease in the number of municipal production pharmacies by 9 times. According to the regional Ministry of Health, 195.5 thousand people (8.2% of the region’s population) are not able to receive pharmaceutical products manufactured at the pharmacy due to the closure of municipal pharmacies in 8 districts. Conclusion. To resolve the most difficult situation, it is necessary at the state level: to determine the need for drugs for extreme production by assortment and analyze the range of analog industrial production available on the global pharmaceutical market, organize their registration in the Russian Federation and subsequent purchases; to consider the possibility of opening in large cities production according to GMP standards and the production of necessary medicines with a longer shelf life for the needs of organizations and the public and their delivery to consumers.
The issues of provision of medical organizations with qualitative, safe and efficient medications are important and actual ones. Recently, medical organizations gave no consideration to these issues because a number of activities in area of circulation of medications was not regulated for medical organizations. In 2017, to provide security of circulation of medications the order № 646n «On approval of the Rules of due practice of storage and transportation of medications for medicinal application» was issued. To evaluate readiness of medical organizations for implementing requirements of the given document, medical organizations of the Irkutsk oblast and the Trans-Baikal krai were analyzed for the purpose of availability of drugstores. The study established that in average drugstores are only in 50% of medical organizations. Among medical organizations with number of beds less than 100 beds, almost 100% of them have no drugstores. The carried-out questionnaire survey concerning awareness of medical specialists about rules of circulation of medications demonstrated inadequate knowledge of rules of prescription and storage of medications. Therefore, it was established that medical organizations are not ready for implementing requirements of the order № 646n from 31.08.2016 of Minzdrav of Russia that can result in decreasing of quality and safety of medications applied in medical organizations. Therefore, a particular attention in medical organizations is to be attended to development and implementation of system of quality targeted to maintenance of rules of circulation of medications. The step-by-step instructions or standard operational procedures are to be developed for all stages of of circulation of medications including receiving, taking-over, storage and application.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.